In a randomized , open-label , single-center trial , recipients of renal transplants ( recipient or donor cytomegalovirus-seropositive ) were randomly allocated ( @:@ ) to @-month prophylaxis with valacyclovir ( @ g four times daily ) or valganciclovir ( @ mg daily ) .